false 0001496671 0001496671 2022-03-31 2022-03-31





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2022



Calithera Biosciences, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-36644   27-2366329

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


343 Oyster Point Blvd. Suite 200

South San Francisco, California

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 870-1000



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, 0.0001 par value   CALA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 2.02.

Results of Operations and Financial Condition.

On March 31, 2022, Calithera Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2021. A copy of this press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.






Press Release, dated March 31, 2022

104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Calithera Biosciences, Inc.
Dated: March 31, 2022      

/s/ Susan M. Molineaux

      Susan M. Molineaux
      President and Chief Executive Officer
EX-99.1 2 d335192dex991.htm EX-99.1 EX-99.1

Exhibit 99.1



Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

— Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022 —

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2021.

“In 2021, we made significant progress in streamlining our clinical development programs, prioritizing our resources, and establishing our focus on biomarker-driven approaches in oncology. Our acquisition of two promising clinical-stage investigational therapies, mivavotinib and sapanisertib, in the fourth quarter significantly contributed to our pipeline of targeted therapies and complemented our in-house programs underway,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “We also announced the first data from our internally-discovered preclinical synthetic lethality target VPS4, and we will present the first data from our novel VPS4A inhibitors at the AACR Annual Meeting. 2022 will be an exciting year as we initiate two phase 2 clinical trials for mivavotinib and sapanisertib. We plan to share data from these trials by the first quarter 2023.”

Fourth Quarter 2021 and Recent Highlights



Transformed Calithera’s precision-oncology pipeline with the acquisition of two clinical-stage compounds with demonstrated single-agent activity; expect to initiate two phase 2 trials in the first half of 2022 with data for both anticipated by the first quarter of 2023.



Mivavotinib (SYK inhibitor): Calithera will explore mivavotinib in the treatment of patients with non-GCB (ABC) DLBCL with and without mutations in MyD88 and CD79. SYK is known to activate multiple cell-signaling pathways in activated B-cell like (ABC) DLBCL. Mivavotinib showed a substantially higher response rate in ABC (53%) compared to GCB (22%) DLBCL in a retrospective analysis of completed trials. In addition, recent preclinical studies have shown enhanced SYK activity and sensitivity to SYK inhibition in DLBCL and other Non-Hodgkin lymphomas harboring mutations in MyD88 and/or CD79, which comprise a distinct genetic subset of ABC DLBCL known to have poor outcomes with standard of care therapy. Approximately 50% of all ABC DLBCL tumors have one or both of these mutations. Data generated from this study could position the company to initiate a study with registrational intent in biomarker-specific populations in DLBCL.



Sapanisertib (Dual mTORC 1/2 inhibitor): Through the phase 2 study, Calithera intends to strengthen the existing data on sapanisertib as a monotherapy in patients with squamous non-small cell lung cancer (sqNSCLC) harboring a NRF2 (NFE2L2) mutation (approximately 15% prevalence), and evaluate its activity in NRF2 wildtype (WT) sqNSCLC. More than 25% of all NSCLC is squamous and these patients have few options beyond standard-of-care PD1 inhibitors and chemotherapy. NRF2-mutated tumors have been shown to have poorer prognosis than NRF2 WT tumors. There are currently no therapies approved specifically for NRF2-mutated cancers, therefore sapanisertib has the potential to address the needs of a substantial underserved patient population. Data generated from this study could position the company to initiate a registrational study in relapsed or refractory squamous NSCLC.



Discovered novel series of VPS4A inhibitors. The first data from Calithera’s preclinical synthetic lethality pipeline will be presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting, on April 8, 2022. The accepted poster will detail Calithera’s discovery of a novel series of VPS4A inhibitors that are currently advancing through lead optimization. VPS4A and VPS4B are paralog ATPases essential for remodeling intracellular organelle membranes. Membrane remodeling is an essential cellular function and loss of function of both VPS4 paralogs is lethal to cells. The preclinical data demonstrate that VPS4A


genetic inhibition in cell lines with loss of VPS4B preferentially showed profound death in cancer cells. Calithera will present the discovery of a series of novel, small-molecule VPS4A inhibitors which have potential in the treatment of VPS4B-deleted tumors.



Discontinued KEAPSAKE trial of telaglenastat in NSCLC. In November 2021, Calithera announced the discontinuation of the phase 2 telaglenastat KEAPSAKE clinical trial in patients with non-squamous NSCLC with genetic mutations in KEAP1/NRF2 based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. Calithera has no plans to continue the development of telaglenastat at this time.



Presented first CB-280 phase 1b data at NACFC. In November 2021, Calithera presented interim data from the Phase 1b trial of CB-280 at the North American Cystic Fibrosis Conference (NACFC). CB-280 was well tolerated, demonstrated linear pharmacokinetics (PK), and showed complete and continuous target inhibition in plasma at doses at or above 100mg. CB-280 also demonstrated robust pharmacodynamic (PD) effects, with rapid and significant dose-proportional increases in plasma arginine, the key driver of NO production. Enrollment and analysis of all four cohorts is now complete and evaluation of next steps is ongoing.



Promoted Emil T. Kuriakose, MD, to chief medical officer. Former vice president and head of clinical development at Calithera, Dr. Kuriakose succeeded Dr. Keith Orford, who was appointed to the Calithera Board of Directors.



Priced a $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock. On March 29, 2022, the Company priced an underwritten public offering of 18,518,519 shares of its common stock at a price to the public of $0.54 per share. Each share of common stock is accompanied by a warrant to purchase one share of common stock at an exercise price of $0.54 per share, which is immediately exercisable and will expire 18 months from the date of issuance, or a short-term warrant, and a warrant to purchase one share of common stock at an exercise price of $0.54 per share, which is immediately exercisable and will expire 5 years from the date of issuance, or a long-term warrant. The gross proceeds to Calithera from the offering are expected to be approximately $10.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on April 1, 2022, subject to customary closing conditions.

Selected Fourth Quarter and Full Year 2021 Financial Results

Cash, cash equivalents and investments totaled $59.5 million at December 31, 2021, which the Company expects, together with proceeds from its $10.0 million public offering, will be sufficient to meet its operating plan through the second quarter of 2023.

Revenue for the full year 2021 was $9.8 million, compared to none in the prior year, and represents payments under collaboration agreements with Incyte and Antengene.

Research and development expenses for the full year 2021 were $53.4 million, compared to $71.0 million in the prior year. The decrease of $17.6 million was primarily due to a decrease in the telaglenastat program. Research and development expenses for the fourth quarter of 2021 were $13.7 million, compared to $17.1 million for the same period last year.

Research and development expenses related to asset acquisition for the full year 2021 were $50.9 million for our acquisition of sapanisertib and mivavotinib in the fourth quarter of 2021, and comprised of an upfront payment of $10.0 million in cash and $40.9 million attributed to the value of the Series A convertible preferred stock on the date issued, estimated using the Black-Scholes option-pricing model.

General and administrative expenses for the full year 2021 were $20.9 million, compared to $20.4 million in the prior year. General and administrative expenses for the fourth quarter of 2021 were $4.6 million, compared to $5.6 million for the same period last year.

Interest and other income, net for the full year 2021 was $0.3 million, compared to $1.3 million in the prior year. Interest and other income, net for the fourth quarter of 2021 was none, compared to $0.1 million for the fourth quarter of 2020.

Net loss for the three months and year ended December 31, 2021, was $69.2 million and $115.1 million, respectively.

Conference Call Information

Calithera will host an update conference call today, Thursday, March 31, at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time. The call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and referring to conference ID 9989324. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website at www.calithera.com. The webcast will be recorded and available for replay on Calithera’s website for 30 days.

About Calithera

Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.

Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “poised” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in preclinical development and clinical trials, including Calithera’s plan to initiate two phase 2 clinical trials for mivavotinib and sapanisertib and plan to share data from these trials by the first quarter 2023, Calithera’s ability to potentially initiate registrational studies in biomarker-specific populations in DLBC and relapsed or refractory squamous NSCLC, the unmet need in the treatment of patients with advanced disease, management’s expectation that Calithera’s cash, cash equivalents and investments will be sufficient to meet its operating plan through the second quarter of 2023, and the timing of the closing of Calithera’s recent public offering of common stock and warrants to purchase common stock. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or be successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera’s stock price. Additional information concerning these and other risk factors affecting Calithera’s business can be found in Calithera’s periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Calithera Biosciences, Inc.

Selected Consolidated Statements of Operations Financial Data

(in thousands, except per share amounts)



     Three Months Ended
December 31,
    Year Ended
December 31,
     2021     2020     2021     2020  



License revenue

   $ —       $ —       $ 9,750     $ —    













Total revenue

     —         —         9,750       —    













Operating expenses:


Research and development

     13,740       17,077       53,455       71,015  

Research and development related to asset acquisition

     50,875       —         50,875       —    

General and administrative

     4,594       5,586       20,853       20,372  













Total operating expenses

     69,209       22,663       125,183       91,387  













Loss from operations

     (69,209     (22,663     (115,433     (91,387

Interest and other income (expense), net

     (1     97       345       1,250  













Net loss

   $ (69,210   $ (22,566   $ (115,088   $ (90,137













Net loss per share, basic and diluted

   $ (0.92   $ (0.32   $ (1.56   $ (1.31













Weighted average common shares used to compute net loss per share, basic and diluted

     75,025       70,588       73,869       68,814  













Calithera Biosciences, Inc.

Selected Consolidated Balance Sheet Financial Data

(in thousands)



     December 31,
    December 31,

Balance Sheet Data:


Cash, cash equivalents and investments

   $ 59,537     $ 115,151  

Working capital

     47,446       100,302  

Total assets

     64,756       125,587  

Total liabilities

     15,672       23,216  

Convertible preferred stock

     40,702       —    

Accumulated deficit

     (491,326     (376,238

Total stockholders’ equity

     8,382       102,371  


Stephanie Wong




Burns McClellan

Lee Roth




Sam Brown, Inc.

Hannah Hurdle



EX-101.SCH 3 cala-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cala-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cala-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g335192g0331134751920.jpg GRAPHIC begin 644 g335192g0331134751920.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Mar. 31, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001496671
Document Type 8-K
Document Period End Date Mar. 31, 2022
Entity Registrant Name Calithera Biosciences, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36644
Entity Tax Identification Number 27-2366329
Entity Address, Address Line One 343 Oyster Point Blvd.
Entity Address, Address Line Two Suite 200
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 870-1000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, 0.0001 par value
Trading Symbol CALA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d335192d8k_htm.xml IDEA: XBRL DOCUMENT 0001496671 2022-03-31 2022-03-31 false 0001496671 8-K 2022-03-31 Calithera Biosciences, Inc. DE 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco CA 94080 (650) 870-1000 false false false false Common Stock, 0.0001 par value CALA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d335192d8k.htm cala-20220331.xsd cala-20220331_lab.xml cala-20220331_pre.xml d335192dex991.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d335192d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d335192d8k.htm" ] }, "labelLink": { "local": [ "cala-20220331_lab.xml" ] }, "presentationLink": { "local": [ "cala-20220331_pre.xml" ] }, "schema": { "local": [ "cala-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cala", "nsuri": "http://www.calithera.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d335192d8k.htm", "contextRef": "duration_2022-03-31_to_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d335192d8k.htm", "contextRef": "duration_2022-03-31_to_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-22-091746-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-091746-xbrl.zip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end